These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 36883925)
1. [Extended release calcifediol and paricalcitol in the treatment of secondary hyperparathyroidism: a network meta-analysis of indirect comparison]. Franchi M; Galassi A; Corrao G G Ital Nefrol; 2023 Feb; 40(1):. PubMed ID: 36883925 [No Abstract] [Full Text] [Related]
2. Paricalcitol and Extended-Release Calcifediol for Treatment of Secondary Hyperparathyroidism in Non-Dialysis Chronic Kidney Disease: Results From a Network Meta-Analysis. Franchi M; Gunnarsson J; Gonzales-Parra E; Ferreira A; Ström O; Corrao G J Clin Endocrinol Metab; 2023 Oct; 108(11):e1424-e1432. PubMed ID: 37235771 [TBL] [Abstract][Full Text] [Related]
3. Real-world assessment: effectiveness and safety of extended-release calcifediol and other vitamin D therapies for secondary hyperparathyroidism in CKD patients. Germain MJ; Paul SK; Fadda G; Broumand V; Nguyen A; McGarvey NH; Gitlin MD; Bishop CW; Csomor P; Strugnell S; Ashfaq A BMC Nephrol; 2022 Nov; 23(1):362. PubMed ID: 36368937 [TBL] [Abstract][Full Text] [Related]
4. The cost-effectiveness of extended-release calcifediol versus paricalcitol for the treatment of secondary hyperparathyroidism in stage 3-4 CKD. Kalantar-Zadeh K; Hollenbeak CS; Arguello R; Snyder S; Ashfaq A J Med Econ; 2020 Mar; 23(3):308-315. PubMed ID: 31726882 [No Abstract] [Full Text] [Related]
5. Evaluating extended-release calcifediol as a treatment option for chronic kidney disease-mineral and bone disorder (CKD-MBD). Cozzolino M; Ketteler M Expert Opin Pharmacother; 2019 Dec; 20(17):2081-2093. PubMed ID: 31675257 [No Abstract] [Full Text] [Related]
6. Where are we now? Emerging opportunities and challenges in the management of secondary hyperparathyroidism in patients with non-dialysis chronic kidney disease. Ketteler M; Ambühl P J Nephrol; 2021 Oct; 34(5):1405-1418. PubMed ID: 34170509 [TBL] [Abstract][Full Text] [Related]
7. Real-World Assessment: Clinical Effectiveness and Safety of Extended-Release Calcifediol. Fadda G; Germain MJ; Broumand V; Nguyen A; McGarvey N; Gitlin M; Bishop CW; Ashfaq A Am J Nephrol; 2021; 52(10-11):798-807. PubMed ID: 34818216 [TBL] [Abstract][Full Text] [Related]
8. Rationale for Raising Current Clinical Practice Guideline Target for Serum 25-Hydroxyvitamin D in Chronic Kidney Disease. Strugnell SA; Sprague SM; Ashfaq A; Petkovich M; Bishop CW Am J Nephrol; 2019; 49(4):284-293. PubMed ID: 30878999 [TBL] [Abstract][Full Text] [Related]
9. A systematic review of the pharmacotherapy of secondary hyperparathyroidism (SHPT) in grades 3-5 Chronic Kidney Disease (CKD). Miedziaszczyk M; Idasiak-Piechocka I; Wiśniewski OW; Lacka K Eur Rev Med Pharmacol Sci; 2022 Jan; 26(1):232-239. PubMed ID: 35049000 [TBL] [Abstract][Full Text] [Related]
10. Calcifediol to treat secondary hyperparathyroidism in patients with chronic kidney disease. Galassi A; Bellasi A; Ciceri P; Pivari F; Conte F; Cozzolino M Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1073-1084. PubMed ID: 28846459 [TBL] [Abstract][Full Text] [Related]
11. Extended-Release Calcifediol: A Data Journey from Phase 3 Studies to Real-World Evidence Highlights the Importance of Early Treatment of Secondary Hyperparathyroidism. Merante D; Schou H; Morin I; Manu M; Ashfaq A; Bishop C; Strugnell S Nephron; 2024 Apr; ():1-10. PubMed ID: 38657576 [TBL] [Abstract][Full Text] [Related]
12. Vitamin D and Secondary Hyperparathyroidism in Chronic Kidney Disease: A Critical Appraisal of the Past, Present, and the Future. Brandenburg V; Ketteler M Nutrients; 2022 Jul; 14(15):. PubMed ID: 35893866 [TBL] [Abstract][Full Text] [Related]
13. Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease. Andress DL; Coyne DW; Kalantar-Zadeh K; Molitch ME; Zangeneh F; Sprague SM Endocr Pract; 2008; 14(1):18-27. PubMed ID: 18238737 [TBL] [Abstract][Full Text] [Related]
15. Treatment of secondary hyperparathyroidism in non-dialysis CKD: an appraisal 2022s. Ketteler M; Bover J; Mazzaferro S Nephrol Dial Transplant; 2023 May; 38(6):1397-1404. PubMed ID: 35977397 [TBL] [Abstract][Full Text] [Related]
16. Comparison between paricalcitol and active non-selective vitamin D receptor activator for secondary hyperparathyroidism in chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials. Cai P; Tang X; Qin W; Ji L; Li Z Int Urol Nephrol; 2016 Apr; 48(4):571-84. PubMed ID: 26748501 [TBL] [Abstract][Full Text] [Related]
17. Extended-release calcifediol in stage 3-4 chronic kidney disease: a new therapy for the treatment of secondary hyperparathyroidism associated with hypovitaminosis D. Cozzolino M; Minghetti P; Navarra P J Nephrol; 2022 Apr; 35(3):863-873. PubMed ID: 34626363 [TBL] [Abstract][Full Text] [Related]
18. Use of Extended-Release Calcifediol to Treat Secondary Hyperparathyroidism in Stages 3 and 4 Chronic Kidney Disease. Sprague SM; Crawford PW; Melnick JZ; Strugnell SA; Ali S; Mangoo-Karim R; Lee S; Petkovich PM; Bishop CW Am J Nephrol; 2016; 44(4):316-325. PubMed ID: 27676085 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of Therapies for Secondary Hyperparathyroidism Associated with Vitamin D Insufficiency in Chronic Kidney Disease. Strugnell SA; Csomor P; Ashfaq A; Bishop CW Kidney Dis (Basel); 2023 May; 9(3):206-217. PubMed ID: 37497207 [TBL] [Abstract][Full Text] [Related]
20. Extended-Release Calcifediol Effectively Raises Serum Total 25-Hydroxyvitamin D Even in Overweight Nondialysis Chronic Kidney Disease Patients with Secondary Hyperparathyroidism. Bishop CW; Strugnell SA; Csomor P; Kaiser E; Ashfaq A Am J Nephrol; 2022; 53(6):446-454. PubMed ID: 35551374 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]